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Background: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder, which may result
from alteration of the gastrointestinal microbiota following gastrointestinal infection, or with intestinal dysbiosis or
small intestinal bacterial overgrowth. This may be treated with antibiotics, but there is concern that widespread
antibiotic use might lead to antibiotic resistance. Some herbal medicines have been shown to be beneficial, but
their mechanism(s) of action remain incompletely understood. To try to understand whether antibacterial properties
might be involved in the efficacy of these herbal medicines, and to investigate potential new treatments for IBS, we
have conducted a preliminary study in vitro to compare the antibacterial activity of the essential oils of culinary and
medicinal herbs against the bacterium, Esherichia coli.
Methods: Essential oils were tested for their ability to inhibit E. coli growth in disc diffusion assays and in liquid
culture, and to kill E. coli in a zone of clearance assay. Extracts of coriander, lemon balm and spearmint leaves were
tested for their antibacterial activity in the disc diffusion assay. Disc diffusion and zone of clearance assays were
analysed by two-tailed t tests whereas ANOVA was performed for the turbidometric assays.
Results: Most of the oils exhibited antibacterial activity in all three assays, however peppermint, lemon balm and
coriander seed oils were most potent, with peppermint and coriander seed oils being more potent than the
antibiotic rifaximin in the disc diffusion assay. The compounds present in these oils were identified by gas
chromatography mass spectrometry. Finally, extracts were made of spearmint, lemon balm and coriander leaves
with various solvents and these were tested for their antibacterial activity against E. coli in the disc diffusion assay.
In each case, extracts made with ethanol and methanol exhibited potent antibacterial activity.
Conclusions: Many of the essential oils had antibacterial activity in the three assays, suggesting that they would be
good candidates for testing in clinical trials. The observed antibacterial activity of ethanolic extracts of coriander,
lemon balm and spearmint leaves suggests a mechanistic explanation for the efficacy of a mixture of coriander,
lemon balm and mint extracts against IBS in a published clinical trial.
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Irritable bowel syndrome (IBS) is a functional gastrointes-
tinal disorder, which affects 10 – 22% of the UK population
and is responsible for 20 – 50% of the workload of gastro-
enterology departments [1]. IBS is characterised by altered
bowel habit, pain, and wind or bloating, which all severely
affect quality of life and may last for decades. IBS can be
classified into subgroups depending on the predominant
bowel symptom, namely constipation-predominant (IBS-
C), diarrhoea-predominant (IBS-D) or alternating between
the two (IBS-A) [2,3]. Post-infectious (PI) IBS may arise
after an episode of acute gastroenteritis [4].
The causes of IBS remain poorly understood, and in-
clude altered gut motor function, visceral hypersensitiv-
ity, abnormal gas handling, alterations in the central
nervous system, mild inflammation, disturbances in
serotonin handling and genetic factors (reviewed in [5]).
Evidence has been mounting in the past decade that al-
terations in the gastrointestinal microbiota may also play
a role in IBS. An early study showed that patients with
IBS-D excreted abnormally high levels of hydrogen com-
pared to healthy individuals, suggesting that there was
abnormal bacterial fermentation of ingested foods [6].
An exclusion diet reduced this. More recently the
gastrointestinal microbiota of IBS patients have been
compared with those from healthy subjects by bacterial
culture or molecular approaches [reviewed in 7,8]. Many
studies have found alterations in the numbers of bacter-
ial species present, or in the abundance of particular
bacterial species. The findings vary, but a common feature
seems to be a reduction in the number of Bifidobacteria
and increased numbers of Firmicutes and Enterobacteria-
ceae in samples from IBS patients compared to control
samples.
IBS has also been linked to small intestinal bacterial
overgrowth, [reviewed in 7,9,10], although this is cur-
rently somewhat controversial [8]. In SIBO, bacterial
numbers can rise from normal levels of 100-4 colony
forming units (cfu) of bacteria/ml in the terminal je-
junum, 100-5 cfu/ml in the proximal ileum and 105-8 cfu/
ml in the terminal ileum [11,12] to 1011 cfu/ml [9]. SIBO
is currently defined as the presence of ≥ 1 × 105 cfu/ml
of colonic bacteria in the jejunum [13,14]. In contrast to
the normal situation in which digestion and absorption
of food is complete before the bolus reaches bacteria in
the colon, in patients with SIBO, ingested food comes
into contact with bacteria in the jejunum and ileum, and
is fermented to produce gas, which has been visualised
in the small intestine by abdominal radiography [15].
SIBO is typically diagnosed by giving patients a drink
containing a poorly digestible sugar such as lactulose,
and analysing their breath gases at intervals (reviewed in
[16,17]). Glucose can also be used. The main gases ex-
creted are hydrogen, which is associated with IBS-D, andmethane, which is associated with IBS-C [18-21]. In one
study, 78% of IBS patients tested positive for SIBO using
the lactulose hydrogen breath test (LHBT) [22].
There is currently some controversy surrounding the
use of lactulose hydrogen breath tests to diagnose SIBO
and, consequently, the role of SIBO in IBS. Early breath
tests diagnosed SIBO if hydrogen was excreted in two
bursts, corresponding to bacterial fermentation in the
small intestine, and in the colon. Later, hydrogen excre-
tion within 90 minutes of lactulose ingestion was taken
as diagnostic of SIBO. However, a recent study has com-
bined LHBTs with scintigraphy to follow the movement
of a radiolabelled tracer through the gastrointestinal
tract [23]. Hydrogen excretion within 90 minutes of
lactulose ingestion was found to correlate with fast oro-
caecal transit rather than SIBO [23], and it has been
suggested that glucose would be a better fermentation
substrate since it is absorbed before it reaches the colon
[17,21,24]. Using the ability to culture 1 × 105 colonic
bacteria from duodenal or jejunal aspirates as the gold
standard for SIBO diagnosis, SIBO was diagnosed in 4%
of IBS patients and healthy control subjects in one study
[14] and in 10.9% of IBS patients in another [25].
Modestly raised bacterial counts (≥ 1 × 103 cfu/ml) were
found in 43% of IBS patients compared to 12% of
healthy controls in the first study [14] and 37% of IBS
patients in the second [25], suggesting that perhaps a
more modest overgrowth of bacteria than previously
thought might contribute to IBS. Of note, lipopolysac-
charide from Gram-negative bacteria speeds up gastro-
intestinal transit [26], raising the possibility that modest
numbers of bacteria in the small intestine could speed
up transit of lactulose (and chyme) to the colon, and
result in a positive LHBT (and IBS) without fermenting
the lactulose themselves.
One Gram-negative bacterium that has been impli-
cated in IBS and SIBO is Escherichia coli. An early study
found E. coli throughout the gastrointestinal tract of pa-
tients with SIBO [27]. E. coli was present in jejunal and
duodenal aspirates from patients with IBS and SIBO
[14,25], in addition to Klebsiella and Enterococcus
species. E. coli was found to be more prevalent in the
mucosal microbiota of IBS patients than those of healthy
control subjects when biopsy specimens were labelled
with fluorescent in situ hybridisation probes [28], and
enteroaggregative strains of E. coli were present in
higher numbers in faecal samples from IBS patients than
those from healthy individuals [29].
There are currently various medicines available to treat
IBS, including fiber, antispasmodic agents, and anti-
depressants to modulate pain perception [30]. Tricyclic
antidepressants block diarrhoea whereas serotonin re-
uptake inhibitors can benefit IBS-C patients by stimulat-
ing gastrointestinal motility [30]. In agreement with the
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are involved in IBS, there has been considerable success
with treatments that reverse this. Clinical trials have
shown that antibiotics can be effective in treating IBS
[31,32]. Successful eradication of SIBO, and reversal of
the symptoms of IBS have been achieved by treating IBS
patients with antibiotics such as metronidazole [33],
neomycin [18], the non-absorbable antibiotic rifaximin
(reviewed in [34]), a combination of rifaximin and cipro-
floxacin [35], or a combination of rifaximin and neomy-
cin for IBS-C patients who produce methane [36].
Reduction of hydrogen or methane excretion was linked
to improvement in gastrointestinal symptoms and rifaxi-
min was particularly effective in treating wind and bloat-
ing. Currently, NICE guidelines do not mention the use
of antibiotics for the treatment of IBS in the UK [37].
SIBO can return after treatment, however [38] and there
is concern that widespread and prolonged treatment
with antibiotics could lead to the emergence of antibiotic
resistant bacterial strains [39]. Indeed rifaximin can be
used to treat infections with Clostridium difficile [40],
but rifaximin-resistant strains have been isolated [41],
and the fact that some IBS patients are carriers of C. dif-
ficile [42] raises the possibility that widespread treatment
of IBS patients with rifaximin could lead to the produc-
tion of more rifaximin-resistant strains of C. difficile.
In contrast, the use of probiotics aims to increase the
number of beneficial bacteria. Probiotics are live microor-
ganisms that, when administered in sufficient numbers,
reduce visceral hypersensitivity, improve gastrointestinal
dysmotility and epithelial integrity, improve immune func-
tion, and modulate the gut microbiota [7,8]. Two recent
systematic reviews showed that probiotics had a moderate
therapeutic benefit in improving IBS symptoms [43,44].
Probiotics reduced the pain of IBS and this was statistically
significant; there was also a significant reduction in
flatulence and a trend towards reduction in bloating [43].
In particular, lactic acid bacteria were shown to be useful,
although the therapeutic benefit stopped when adminis-
tration of the probiotics was terminated [44]. Related to
this, prebiotics have also been shown to be of modest
benefit in treating IBS – these are nondigestible dietary
supplements that increase the growth of beneficial bac-
teria. One clinical trial showed that ingestion of galacto-
oligosaccharide stimulated the growth of bifidobacteria
and alleviated IBS symptoms [45]. Finally, faecal trans-
plantation has been successfully used to modulate the
gastrointestinal microbiota in a small number of IBS
patients (reviewed in [46]). This has the advantage that
the entire community of colonic bacteria is transplanted,
rather than the one or two bacterial species that might be
present in a probiotic preparation.
An alternative approach to the treatment of IBS is the
use of dietary modifications to reduce the amount offermentable substrates available to the gastrointestinal
microbiota. Early work pioneered the use of an exclusion
diet consisting of one meat, one fruit and distilled or
spring water for a week. If the patient’s IBS symptoms
resolved, foods were reintroduced one at a time and any
resulting IBS symptoms noted [47]. Two thirds of the
patients reported resolution of their symptoms on the
exclusion diet, and wheat, corn, dairy products, coffee,
tea and citrus fruits were found to provoke IBS symp-
toms, even in a double blind food challenge. A more
relaxed exclusion diet consisting of fish and meat (apart
from beef ) and rice, and lacking dairy products, citrus
fruits, yeast, tap water and caffeinated drinks, reduced
hydrogen excretion by IBS patients in addition to resolv-
ing their symptoms [6]. This exclusion diet has been de-
scribed in more detail [48]. These and other exclusion
diets have been found to be useful under medical super-
vision by NICE [37], which also recommended that it
may be helpful for IBS patients to limit both their fibre
intake, and to eat no more than three portions of fruit
per day. A recent approach to dietary manipulation has
rationalised knowledge of the foods that commonly pro-
voke IBS symptoms with an understanding of their
chemical composition, namely the adoption of a diet low
in FODMAPs (fermentable oligosaccharides, disaccha-
rides, monosaccharides and polyols) [49]. This involves
avoiding 1) fruits that are high in fructose, 2) dairy prod-
ucts apart from butter and hard cheese, because they
contain lactose, 3) vegetables, legumes and cereals (in-
cluding wheat) that contain the oligosaccharides fructans
or galactans and 4) fruits, vegetables and artificial sweet-
eners that contain polyols [49]. Restriction of fructose
and fructans led to an improvement in gastrointestinal
symptoms in three out of four IBS patients with fructose
malabsorption [50]. When other patients who had
attained remission of their IBS symptoms for 3 –
36 months on a low FODMAPs diet were rechallenged
with fructose or fructans in a placebo-controlled, double
blind clinical trial, their symptoms returned, indicating
that the fructose and fructans could provoke IBS symp-
toms [51]. In another double blind trial by the same
group (in Australia), IBS patients on a high FODMAPs
diet excreted more hydrogen and experienced more
gastrointestinal symptoms than patients on a low FOD-
MAPs diet [52]. More recently, a British group has com-
pared the efficacy of a low FODMAPs diet in reducing
IBS symptoms with the standard dietary guidelines rec-
ommended by NICE: more of the patients on the low
FODMAPs diet reported an improvement in their symp-
toms than the patients following the NICE dietary guide-
lines [53], this was especially true for wind and bloating.
Herbal medicines are also used to treat IBS, both in
mainstream medicine, and in complementary and alter-
native medicines from different traditions; these have
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Peppermint (Mentha piperita) oil has been recommended
for the treatment of IBS by NICE guidelines [37] and is
widely prescribed in the form of enteric-coated pepper-
mint oil tablets; it has antispasmodic activity [57,58].
Grigoleit and Grigoleit performed a meta-analysis of
sixteen placebo-controlled clinical trials studying the use
of enteric-coated peppermint oil capsules to treat IBS, and
found that the overall success rate of peppermint oil cap-
sules was 58% compared to 29% for placebo [59]. They
concluded that “peppermint oil…may the drug of first
choice in IBS patients with non-serious constipation or
diarrhoea to alleviate general symptoms and to improve
quality of life e.g. pain or bloating”. A recent meta-analysis
of four clinical trials confirmed this view [60]. In fact
peppermint oil, in the form of a preparation called Pepper-
mint water BP1973, has long been used to treat dyspepsia,
flatulence and stomach cramps, and has just been awarded
a traditional herbal registration certificate [61]. Another
herbal preparation that has shown promise in the treat-
ment of IBS is IberogastW (also called STW-5), a liquid
formulation of nine different herbs, namely bitter candy-
tuft, or clown’s mustard plant (Iberis amara), German
chamomile (Matricaria recutita) flowers, angelica (Angel-
ica archangelica) root, caraway (Carum carvi) fruit, lemon
balm (Melissa officinalis) leaves, greater celandine (Cheli-
donium majus) aerial parts, liquorice (Glycyrrhiza glabra)
root, milk thistle (Silybum marianum L) and peppermint
oil [62]. In a randomised, double-blind, placebo-controlled
trial, STW 5 (IberogastW) reduced abdominal pain, prob-
lems with bowel habit and flatulence in IBS patients [63].
IberogastW is also effective against functional dyspepsia
[64] and is widely prescribed in Germany with more than
a million prescriptions being written for it in Germany in
2002 [65]. IberogastW has been shown to have antispas-
modic, anti-inflammatory and antioxidant activity, and
also acts as a secretagogue (reviewed in [55,62]). A similar
mixed herbal extract, called carmint, which consists of
herbal extracts of lemon balm, spearmint (Mentha
spicata) and coriander (Coriandrum sativum), reduced ab-
dominal pain and bloating in IBS patients in a clinical trial
[66]. IBS-D patients were prescribed loperamide, and IBS-
C patients were prescribed psyllium, plus either carmint
or placebo; there was a significant reduction in symptoms
in the IBS patients taking carmint compared to those tak-
ing the placebo after eight weeks.
Herbs have traditionally been used to treat bacterial
infections [67], for instance lavender (Lavandula
angustifolia) oil and tincture were used to treat wounds
before the First World War. Many culinary herbs have
been reported to possess antibacterial properties [67,68],
as have the essential oils of these herbs [69]. Many
herbs, for instance fennel (Foeniculum vulgare), lavender,
peppermint, rosemary (Rosmarinus officinalis) and sage(Salvia officinalis), have been used traditionally as diges-
tives, aiding digestion or reducing flatulence [67,68,70].
Our hypothesis is that the digestive properties of a par-
ticular herb may be linked, at least in part, to the herb’s
antibacterial action. Essential oils and herbal extracts have
an advantage over conventional antibiotics since they may
contain several antibacterial compounds that act in differ-
ent ways, so that it would be more difficult for bacteria to
develop resistance. For instance lemon grass (Cymbopogon
citratus) essential oil contains at least sixteen compounds
[71] and successfully inhibited the growth of Helicobacter
pylori over many bacterial generations, whereas antibiotic
resistant H. pylori emerged after ten passages on plates
containing only the antibiotic clarithromycin [72].
NICE guidelines recommend that further research
should be conducted to study the possibility of using
herbal medicines to treat IBS. With this in mind, in
order to increase our understanding of the mechanism
of action of herbal medicines that have been shown to
be beneficial in treating IBS, and to identify other essen-
tial oils or extracts that would be useful candidates for
clinical trials, we have conducted a preliminary study
in vitro using a non-pathological strain of E. coli. We
have compared the antibacterial activity of essential oils
of a range of herbs that have been used traditionally as
digestives, in three separate assays. We found that the
essential oils with the most potent antibacterial activity
in the three assays were those of coriander seed,
lemon balm and peppermint. Interestingly, essential
oils or extracts of coriander, lemon balm and pepper-
mint are all present in herbal medicines that have
been validated for use in the treatment of IBS by at
least one clinical trial (without their mechanism of ac-
tion being ascribed to an antibacterial effect). We
identified the compounds present in the coriander
seed, lemon balm and peppermint essential oils that
we had used, by thermal desorption gas chromatog-
raphy mass spectrometry. Finally we tested the anti-
bacterial activity of extracts of coriander, lemon balm
and spearmint leaves that had been made with various
solvents to determine whether ethanolic tinctures of
these herbs (which have been used instead of essential
oils in some of the IBS medicines) would have antibac-
terial activity. This has allowed us to propose a new
mechanism of action for these herbal medicines, and
suggest some other herbs/essential oils that could be
tested in further clinical trials.
Methods
Materials
E. coli strain DH5α, was obtained from Dr. Geertje van
Keulen (Swansea University). All essential oils (listed in
Table 1) were obtained from Amphora Aromatics,
Bristol, UK. Coriander plants were obtained from Tesco
Table 1 Summary of results of antibacterial activity of essential oils




Activity in zone of clearance
assay
Coriander seed Coriandrum sativum ++ +++ +++
(0.0053) (5.82 × 10-5) (0.0002)
Fennel Foeniculum vulgare + +++ +
(0.0003) (8.01 × 10-6) (0.0027)
Grapeseed Vitis vinifera - - -
(0.3216)
Lavender Lavendula angustifolia + ++ +
(0.0039) (0.0031) (0.0011)
Lemon balm Melissa officinalis ++ ++ +++
(0.0041) (0.0008) (0.0014)
Lemon grass Cymbopogon citratus ++ ++ +
(0.0004) (0.0030) (0.0003)
Mandarin Citrus reticulata ++ +++ +
(0.0092) (3.39 × 10-5) (0.0484)
Neem Azadirachta indica - ND -
Peppermint Mentha piperita ++ +++ +++
(0.0390) (3.14 × 10-5) (0.0000)
Pine Pinus sylvestris +++ ++ ++
(0.0027) (0.0003) (0.0001)
Rosemary Rosmarinus officinalis + ++ +
(0.0000) (0.0085) (0.0036)
Sage Salvia lavendulifolia + +++ +
(0.0022) (3.39 × 10-6) (0.0021)
Tea tree Melaleuca alternifolia +++ +++ +++
(0.0079) (5.83 × 10-6) (0.0000)
Thyme Thymus vulgaris +++ +++ +
(0.0020) (5.84 × 10-5) (0.0193)
Ylang ylang Cananga odorata var. genuina +/- + -
(0.0075) (0.0477)
Crosses denote the magnitude of the antibacterial activity; the numbers in brackets are the P values obtained from t tests comparing the size of the halos
produced with the essential oils with those produced by grapeseed oil for the disc diffusion and zone of clearance assays, and from comparing the A600 of the
turbidometric assay in the presence of essential oil after 6 hours with that lacking essential oil.
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the Swansea City Council Botanic Gardens shop and
spearmint plants were obtained from the Homebase
superstore in Swansea. All chemicals were obtained from
Sigma Chemical Company (Poole, Dorset) unless other-
wise stated.
Disc diffusion assay: growth inhibition
A modification of the Kirby-Bauer disc diffusion assay
was used [73]. E. coli bacteria were grown overnight in
Luria Bertani medium [74] at 37°C with shaking at
150 rpm for 16 h and 100 μl of the resulting culture
were spread onto LB agar plates [74] as a lawn. Sterile
7 mm glass fibre discs (Whatmann GF-C, Sigma, Poole,Dorset, UK) were immediately placed on the surface of
the bacterial plates and essential oil (10 μl) was added to
each disc. Grapeseed (Vitis vinifera seed) oil was
included as a negative control, since it was not expected
to exhibit any antibacterial activity [75]. Following
growth at 37°C for 24 h, the zones of inhibition (halos)
were measured with a ruler to an accuracy of 0.5 mm.
An absence of antibacterial activity would produce a
halo of 7 mm diameter, the size of the glass fibre discs.
Disc diffusion assays were also carried out using 10 μl of
the following antibiotic solutions in order to compare
the antibacterial activities of some essential oils with
those of the antibiotics: ampicillin (100 mg/ml in water),
neomycin (10 mg/ml in water), and rifaximin (100 mg/ml
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out with water or methanol for comparison.
Disc diffusion assay: zone of clearance
This assay was adapted from that of Bexfield et al. [76]. E.
coli bacterial overnight culture (100 μl) was spread aseptic-
ally onto LB agar plates, and grown overnight at 37°C for
16 h. Sterile 7 mm glass fibre discs containing 10 μl essen-
tial oil were added to each disc. Grapeseed oil was used as
a control. The plates were grown at 37°C for a further
2 days and the diameters of the zones of clearance were
measured with a ruler to an accuracy of 0.5 mm.
Turbidometric assay
E. coli DH5α were grown in LB medium for 16 h over-
night and the concentration of bacteria in the overnight
culture was determined by measuring A600 [77]. Essen-
tial oil (100 μl) was added to 102 ml LB medium in a
500 ml conical flask. The flask was shaken to mix the
contents and 2 ml of the liquid were removed to cu-
vettes for use as blanks. Bacterial overnight culture con-
taining 1 × 108 E. coli cfu was added to the flask, which
was shaken to mix the contents. A sample was removed
to a cuvette and the A600 was measured against the
blank. The bacteria were grown at 37°C with shaking at
150 rpm and the A600 was measured after 1 h and every
20 min thereafter for a further 5 h by sampling from the
flask. Controls were performed, either lacking essential
oil, or containing 100 μl grapeseed oil.
GC/MS of essential oils
The chemical composition of the oils was evaluated by
injecting samples of dilute oil onto sorbent tubes, then
extracting with thermal desorption for analysis using gas
chromatography with mass spectrometry (GC/MS).
Oils were diluted to 1 part in 1000 in HPLC grade
methanol and injected in 10 μL quantities into sorbent
tubes (6.4 mm diameter stainless steel containing Tenax
TAW sorbent). A stream of helium was used to remove
the methanol over 3 minutes at a flow rate of 30 ml/min
and at room temperature. Sample tubes containing the
oils were loaded into an Ultra unit (Markes Inter-
national, Llantrisant, UK) for automated processing via a
Unity thermal desorption unit and fed with inert helium
at 10 psi to desorb the tubes in a 30 ml/min stream of
inert helium at 300°C for 5 minutes. To further concen-
trate, the flow was driven onto a cold trap (U-T11GPC,
general purpose graphitized carbon C4/5-C30/32) set
at -10°C. The trap was then desorbed at 300°C for 3 mi-
nutes with 50 ml of the sample stream vented and the
remainder injected into the GC (Agilent Technologies
6890 N gas chromatograph). The VOCs were separated
using a capillary column (30 m × 0.25 mm id, HP-5MS
film thickness 0.25 μm). The column temperature wasinitially set at 40°C and then increased steadily to 200°C
at a rate of 5°C/min. Mass spectrometry (Agilent
Technologies 5973 network mass selective detector) was
used in electronic ionisation mode and mass spectral
data obtained in the SCAN mode with a mass range m/z
40 - 550. Each tube was run twice to prevent carry-over
of volatiles onto the cold trap in subsequent samples
and to check for VOCs inherent in the system. Three
samples were taken for each type of oil.
Automated peak detection and baseline correction was
used to calculate peak area and retention time (RT) for
each compound. Using an automated library search
function in the Chemstation GC/MS software (Agilent
Technologies), VOCs were tentatively identified using
the NIST 98 mass spectral library (The National Insti-
tute of Standards and Technology) at the apex of each
peak and utilising probability based matching (PBM).
The list of compounds generated was re-checked using
forward-search matching and compared with the litera-
ture. The consistency of the mass response across the
retention time range was checked by injecting aliquots
of toluene, xylene and dodecane directly into sorbent
tubes (1 part in 10,000 in methanol), and measuring the
area under the curve. These compounds gave very simi-
lar mass responses for given concentrations, indicating
that the area under the curve for each compound could
be used to approximately indicate the abundance level.
The compounds that make up essential oils are often
present in a range of optical and structural isomers with
similar mass spectra and sometimes differing retention
times. It is therefore difficult to precisely identify all
compounds [78]. The separation and analysis methods
employed do not allow identification of optical isomers,
or all structural isomers, so while the compounds
present will probably be specific optical and structural
isomers, compound identification has been limited to
generic, rather than specific, isomeric structures.
Preparation of plant extracts
Extracts were made from freeze dried coriander, lemon
balm and spearmint leaves with various solvents using a
modification of the methods of Wong and Kitts [79] for
coriander and lemon balm or Lopez et al. [80] for mint.
In each case, freeze dried leaf material was ground or
chopped with a razor blade, resuspended in 10 ml solv-
ent and left to macerate at room temperature for 18 or
24 h. The extracts were filtered through filter paper
(Whatmann No. 1, Fisher Scientific. Loughborough, UK)
and either used neat, or dried in a rotary evaporator set
to 50°C and resuspended in the appropriate solvent. Ex-
tracts were stored at –20°C and equilibrated to room
temperature before use. The extracts were tested in disc
diffusion assays. Negative controls consisted of the solv-
ent that had been used to prepare the extract, in each
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the positive control.Statistics
The null hypothesis states that there is no difference be-
tween the diameter of the halos in the disc diffusion assays
or the A600 values in the turbidometric assays, and those
of the controls. Two-tailed independent samples t tests
were carried out to determine the probability that the
diameter of the halos in the disc diffusion asays differed
from those of the controls by chance. The results of the
turbidometric assays were analysed by a one-way ANOVA
and post-hoc test using SPSS.B
C
Figure 1 Antibacterial activity of essential oils in disc diffusion assays
bacterial lawn resulting from the antibacterial activity of lemon balm and c
from three disc diffusion assays showing the effect of essential oils on the
replicates of a single disc diffusion assay showing the effect of essential oil
out to determine whether the halos produced by rifaximin were significan
Significance levels obtained from two-tailed t tests are denoted by stars: * =
significant (P < 0.001).Results
Disc diffusion assays to examine the antibacterial activity
of essential oils against E. coli
Plant essential oils were tested for their antibacterial
activity against E. coli DH5α by disc diffusion assays (see
Figure 1). The largest halo diameters were produced by
pine (Pinus sylvestris), thyme (Thymus officinalis) and tea
tree (Melaleuca alternifolia) oils, with mean halo diame-
ters of 38.7 +/- 3.3 mm for thyme, 31.3 +/- 3.7 mm for
pine and 27 +/- 1.5 mm for tea tree, against a mean halo
diameter of 7 +/- 0 mm for the grapeseed oil negative con-
trol. The results were highly significantly different from
the control in each case (P < 0.01). This demonstrates that
these oils have strong antibacterial activity towards E. coli.. A) Example of disc diffusion assay plate showing the halos in the
oriander oils against E. coli DH5α. B) Graph of mean halo diameters
growth of E. coli, +/- SEM. C) Graph of mean halo diameters from four
s or antibiotics on the growth of E. coli, +/- SEM. t tests were carried
tly different from the solvents, essential oils or other antibiotics.
significant (P < 0.05); ** = highly significant (P < 0.01); *** = very highly
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more moderate, but still statistically significant level with
coriander seed (mean halo diameter of 18 +/- 2.4 mm),
lemon grass (18 +/- 1 mm), peppermint (17.7 +/- 3.5 mm),
lemon balm (16 +/- 1.5 mm), fennel (14 +/- 0.6 mm), sage
(14 +/- 2 mm), rosemary (13.3 +/- 0.3 mm), lavender
(13 +/- 1 mm) and mandarin (Citrus reticulata) (12.7 +/-
1.2 mm). The antibacterial activity of peppermint essential
oil was statistically significantly different from that of the
grapeseed oil control whereas the activities of coriander
seed, lemon balm, sage, lavender and mandarin essential
oils were highly significantly different and those of lemon
grass, fennel and rosemary very highly significantly differ-
ent from that of the control. Ylang ylang (Cananga odorata
var. genuina) demonstrated only a very weak antibacterial
activity against E. coli (mean halo diameter = 8.7 +/-
0.3 mm), which was, however, highly statistically signifi-
cant. Like grapeseed oil, neem (Azadirachta indica) oil did
not exhibit any antibacterial effect in this assay.
Disc diffusion assays were also conducted to compare
the diameter of the halos produced by the antibiotic rifaxi-
min (which has been shown to reverse SIBO in clinical tri-
als) with halos produced by two other antibiotics:
neomycin (used to treat SIBO and IBS clinically) and
ampicillin (used to inhibit the growth of E. coli DH5a in
the laboratory), and essential oils of peppermint, coriander
seed and spearmint. The results are shown in Figure 1C.
As expected, the mean diameter of the halos produced by
rifaximin in the disc diffusion assays was larger and very
highly significantly different from that produced by the
methanol control, demonstrating that the rifaximin solu-
tion had antibacterial activity against E. coli DH5α which
was not due to the methanol that was used to dissolve the
rifaximin. The halos produced by neomycin and ampicillin
were larger than those produced by rifaximin, showing
that these antibiotics are more potent at killing/inhibiting
the growth of E. coli in the disc diffusion assay than rifaxi-
min, and the results were very highly significant. Interest-
ingly, there was no significant difference between the
diameter of the halos produced by rifaximin with those pro-
duced by spearmint essential oil, suggesting that, at least in
this assay, spearmint essential oil is just as potent as rifaxi-
min. Moreover, the halos produced by peppermint and
coriander seed essential oils were larger and either signifi-
cantly different, or very highly significantly different from
the rifaximin in each case, demonstrating that peppermint
and coriander seed essential oils have a larger antibacterial
activity against E. coli DH5α in this assay than rifaximin.
Turbidometric assays to examine the antibacterial activity
of essential oils against E. coli
The antibacterial activities of the various essential oils
against E. coli were also examined using turbidometric
assays since this method is said to be more sensitivethan the disc diffusion assay [81]. It can also reveal
whether the oil slows down the growth of bacteria, or in-
hibits growth altogether. The results are shown in Figure 2.
The Absorbance600 values obtained after 360 minutes, cor-
responding to bacterial growth were analysed by one way
ANOVA. There were significant differences in variance
detected between the mean absorbance values at t = 360
mins, F14, 30 = 3253.911, p < 0.0001. Post hoc extraction
(Least Significant Difference method) revealed that there
were significant differences between the standard and the
samples containing the essential oils, with the exception of
grapeseed oil (p < 0.05), i.e. all of the essential oils inhib-
ited the growth of E. coli DH5α in the turbidometric assay,
except for grapeseed oil.
In fact grapeseed oil produced a small and reprodu-
cible stimulation of the growth of E. coli compared to
the standard lacking essential oil in this assay (Figure 2),
suggesting that it is acting as a prebiotic. The other oils
all inhibited the growth of E. coli. Ylang ylang oil inhib-
ited E. coli growth by a small amount whereas rosemary,
lavender, lemon balm, lemon grass, fennel and pine
inhibited E. coli growth more strongly. The curves for
samples containing these oils were exponential, indicat-
ing that there was some bacterial growth, albeit less than
in the control. Mandarin, peppermint, sage, tea tree,
thyme and coriander seed essential oils almost com-
pletely inhibited the growth of E. coli in the turbido-
metric assay, the growth curves were flat.
Samples containing lemon balm, lemon grass or man-
darin essential oils had a high OD600, even at the start of
the bacterial incubation, although the absorbances did
not rise very steeply after that and, in the case of manda-
rin oil, fell. This should not have happened and cannot
be attributed to light absorbance at 600 nm by coloured
compounds in the oils, since the spectrophotometer was
zeroed against LB blanks containing the appropriate oil.
The effect was reproducible with certain oils, but the
reason for it is not clear – perhaps some of the oils
formed light scattering micelles.
Zone of clearance assay
In order to investigate whether the essential oils could
lyse E. coli that were already present rather than inhibit-
ing their growth, zone of clearance assays were con-
ducted, ie glass fibre discs containing essential oils were
placed on pre-existing E. coli lawns, and halos were
allowed to develop. This was important because treat-
ments to target SIBO would need to kill bacteria that
were already present in the small intestine, rather than
simply inhibiting their growth.
Coriander seed, lemon balm, peppermint, pine and tea
tree oils exhibited strong antibacterial activity in the zone
of clearance assay (see Figure 3), with mean halo diame-










Figure 2 Antibacterial activity of essential oils in turbidometric assays. Graphs showing the results of turbidometric assays to examine the
effect of plant essential oils on the growth of E. coli in liquid culture. Data are the mean of three experiments +/- SEM.
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http://www.biomedcentral.com/1472-6882/13/338peppermint, 24.1 +/- 3.1 mm for lemon balm, 22.8 +/-
2.0 mm for coriander seed and 19.1 mm +/- 1.4 mm for
pine essential oils, compared to a mean halo diameter
of 7 +/- 0 mm for grapeseed oil. t tests revealed that the
halo diameters for coriander seed, peppermint, pine and
tea tree were very highly significantly different from thoseof the grapeseed oil control (P < 0.001) whereas the halo
diameters for lemon balm were highly significantly differ-
ent from those of the control (p < 0.01). Many of the other
oils exhibited a small effect in the zone of clearance assay,
namely fennel (mean halo diameter: 11.6 +/- 0.9), rose-
mary (11.4 +/- 0.9 mm), thyme (10.6 +/- 1.1 mm),
Figure 3 Antibacterial activity of essential oils in zone of clearance assays. Graph showing mean halo diameters +/- SEM obtained from
four separate zone of clearance assays to determine the ability of plant essential oils to lyse E. coli. Significance levels obtained from two-tailed
t tests are denoted by stars: * = Significant, P < 0.05; ** = highly significant, P < 0.01; *** = very highly significant, P < 0.001.
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sage (10.3 +/- 0.6 mm) and lemon grass (10.1 +/-
0.4 mm). The halos for mandarin and thyme were signifi-
cantly different from those of the grapeseed oil control
whereas those for fennel, lavender, rosemary and sage
were highly significantly different and the halos for lemon
grass were very highly significantly different from the
halos produced by the grapeseed oil control.
The results of the disc diffusion assays, the turbido-
metric assays and the zone of clearance assays have been
summarised in Table 1. It can be seen that coriander
seed, lemon balm, peppermint, pine and tea tree essen-
tial oils performed well in all three assays.
Mass spectrometry of coriander seed, lemon balm and
peppermint essential oils
Since coriander, lemon balm and peppermint are all culin-
ary herbs and their essential oils are all on the list of food
additives that are generally recognised as safe to ingest [82],
thermal desorption gas chromatography mass spectrometry
(GC/MS) was conducted on the coriander seed, lemon
balm and peppermint essential oils used in this study to
identify the compounds present, and to assess whether the
oils were representative of their respective types.
Sample chromatograms are shown in Figure 4. Lists of
the main compounds detected by GC/MS are tabulated
for lemon balm, peppermint and coriander seed oils in
Tables 2, 3 and 4 respectively. The approximate concen-
tration is calculated as the mean of three samples ofeach essential oil. Compound identification is tentative
and based on correlation with a mass spectra database.
The compounds shown are those present in approximate
concentrations of 1% or more and were primarily in the
form of terpenes or terpinoids.
The lemon balm oil primarily consisted of citronellal,
geraniol/nerol (alcohol form of citral) and citronellol,
with smaller amounts of citronellol acetate, isopulegol
and limonene (see Table 2). It was unusual in containing
only a low level of citral, which consists of a mixture of
the two isomeric compounds geranial and neral, and is
usually reported to be a major constituent of lemon
balm oil [83-85], although lemon balm oils with only
slightly higher levels of citral than ours have been docu-
mented [86]. Some of the lower concentration com-
pounds gave similar library matches to one another
despite being detected at different retention times. This
suggests similar structures, which could not be ad-
equately distinguished by the techniques used in the
study, and these compounds have been labelled as “un-
known”. The peppermint oil consisted primarily of
menthol and menthone, with smaller amounts of
eucalyptol (1,8-cineole), menthyl acetate and caryophyl-
lene (see Table 3), which is in agreement with other pub-
lished analyses of peppermint oil [87-89]. The coriander
seed oil consisted primarily of linalool, with smaller
amounts of cymene, camphor, pinene, linalyl acetate,
limonene and terpinene (see Table 4). The compounds
were similar to those reported elsewhere for coriander
Figure 4 Chromatograms of lemon balm, peppermint and coriander oils.
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study was representative of its type. Our analysis could
not differentiate between isomers and many compounds
present at lower concentrations were not adequately
identified, and require further investigation.
Disc diffusion assays to examine the effect of plant
extracts on the growth of E. coli
The experiments in the earlier sections showed that the
essential oils of coriander seed, lemon balm and pepper-
mint exhibited antibacterial activity against E. coli in
three separate assays, suggesting that they might reduce
numbers of E. coli in the gastrointestinal tract, and thus
be able to reverse intestinal dysbiosis and SIBO, and
resolve the symptoms of IBS. In fact, a clinical trial has
shown that a mixed herbal extract of coriander, lemon
balm and spearmint (called carmint) reduced the symp-
toms of IBS after eight weeks [66]. Presumably carmint
(said to contain “total extracts” of the three herbs [66])
is an ethanolic extract of coriander, lemon balm andspearmint leaves (and possibly stems), although this is
not explicitly stated. The mechanism of action under-
lying carmint’s efficacy in treating IBS has not been
described. In order to determine whether ethanolic ex-
tracts of coriander, lemon balm and spearmint leaves
would have antibacterial activity, which could explain
carmint’s efficacy, we made extracts of coriander, lemon
balm and spearmint leaves using ethanol or various
other solvents of differing polarity, and carried out disc
diffusion assays. It should be noted that even if the
extracts made with solvents other than ethanol had anti-
bacterial activity, they would be useless therapeutically
because the solvents would be toxic. The solvents were
used as negative controls, since some would exhibit anti-
bacterial activity in their own right, and the appropriate
essential oil was used as the positive control.
Coriander leaf extracts
The results for disc diffusion assays with coriander leaf
extracts are shown in Figure 5. The mean halo diameter
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chloroform is no larger than those produced by the chloro-
form control (8.7 +/- 0.3 mm versus 7.7 +/- 0.3 mm), thus
the chloroform extract of coriander does not exhibit any
antibacterial effects against E. coli. The coriander extract
made with DMSO seemed to exhibit antibacterial activity,
with a mean halo diameter of 16 +/- 3 mm, compared
to 7.7 +/- 0.3 mm for the DMSO control, although the re-
sults fell short of significance. The ethanolic extract of cori-
ander exhibited potent antibacterial activity, with a mean
halo diameter of 22.7 +/- 1.2 mm versus 10.7 +/- 0.9 mm
for the ethanol control, with the results being highly sig-
nificant. The coriander extract made with ethyl acetate was
not significantly different from the ethyl acetate control
(mean halo diameters of 14.3 +/- 2.9 mm versus 9.7 +/-
0.9 mm). Finally, the methanolic extract of coriander also
exhibited strong antibacterial activity, with a mean halo
diameter of 25 +/- 3.5 mm versus 13 +/- 3.6 mm for the
methanol control, with the results being statistically signifi-
cant. Thus the ethanolic and methanolic extracts of corian-










Caryophyllene 1.24in the disc diffusion assay, suggesting that the antibacterial
compounds have been extracted into these polar solvents.
Lemon balm extracts
The results for disc diffusion assays with lemon balm
extracts are shown in Figure 6. Lemon balm extract
made with chloroform did not exhibit any antibacterial
activity against E. coli, since the mean halo diameter was
7.7 +/- 0.3 mm for both the chloroform control and the
chloroform extract. Extracts of lemon balm made with
DMSO exhibited moderate antibacterial activity against
E. coli, with a mean halo diameter of 12.3 +/- 1.2 mm
versus 7 +/- 0 mm, with the results being statistically
significant. More potent antibacterial activity was
observed with lemon balm extracts made with ethanol,
ethyl acetate and methanol, with mean halo diameters of
18 +/- 2.5 mm, 20.7 +/- 3 mm and 19 +/- 2 mm respect-
ively versus 9 +/- 1.5, 10.3 +/- 1.8 and 8 +/- 0 mm
respectively, for the solvent controls. The results for the
extracts made with ethanol and ethyl acetate were statis-
tically significant, and those for the methanolic extract
were highly statistically significant. This suggests that
the antibacterial compounds in lemon balm have been
extracted into ethyl acetate, methanol and ethanol.
Spearmint extracts
The results for disc diffusion assays with spearmint
extracts are shown in Figure 7. Spearmint extracts made
with dichloromethane showed very little antibacterial
effect against E. coli, producing halos with an average
diameter of 8.8 +/- 0.2 mm compared to 8.0 +/- 0.0 mm
for the dichloromethane control. The results were highly
statistically significant, however. Spearmint extracts
made with ethanol inhibited the growth of E. coli, pro-
ducing halos of average diameter 16.2 +/- 1.2 mm versus
8.8 +/- 0.2 mm for the ethanol control, and the results
were highly significant. Spearmint extracts made with
ethyl acetate displayed antibacterial activity, producing
halos of average diameter 14.3 +/- 0.7 mm versus average
halo diameters of 11.0 +/- 0.6 mm for the solvent control;
the results were statistically significant. Spearmint extracts
prepared with methanol displayed a similar level of
Figure 5 Antibacterial activity of coriander extracts in disc diffusion assays. Graph showing mean halo diameters +/- SEM obtained from
three separate disc diffusion assays to determine the effect of coriander extracts made with various solvents on the growth of E. coli. Significance
levels obtained from two-tailed t tests are denoted by stars: * = Significant, P < 0.05; ** = highly significant, P < 0.01; *** = very highly significant,
P < 0.001. Significance levels for coriander essential oil were not determined.
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of 13.2 + 0.4 mm versus 8.8 +/- 0.4 mm for the methanol
control. The results were highly significant. This suggests
that the antibacterial compounds in spearmint have been
extracted into ethanol, ethyl acetate and methanol.Figure 6 Antibacterial activity of lemon balm extracts. Graph showing
experiments to determine the effect of lemon balm extracts made with variou
two-tailed t tests are denoted by stars: * = Significant, P < 0.05; ** = highly sign
for disc diffusion assays with lemon balm essential oil were not determined.The results show that ethanolic extracts of coriander,
lemon balm and spearmint leaves have antibacterial ac-
tivity, and thus that the mixed herbal extract carmint
(which contains extracts of coriander, lemon balm and
spearmint) would be expected to have antibacterialmean halo diameters +/- SEM obtained from three separate disc diffusion
s solvents on the growth of E. coli. Significance levels obtained from
ificant, P < 0.01; *** = very highly significant, P < 0.001. Significance levels
Figure 7 Antibacterial activity of spearmint extracts. Graph showing mean halo diameters +/- SEM from three disc diffusion assays to
determine the effect of spearmint extracts made with various solvents on the growth of E. coli. Significance levels obtained from two-tailed t tests
are denoted by stars: * = Significant, P < 0.05; ** = highly significant, P < 0.01; *** = very highly significant, P < 0.001. Significance levels for disc
diffusion assays with peppermint essential oil were not determined.
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cacy as a treatment for IBS.
Discussion
The data above show that pine, tea tree and thyme oils
all exhibited strong antibacterial activity against E. coli
in the disc diffusion assay, with coriander seed, lemon
balm, lemon grass, mandarin and peppermint essential
oils having more moderate antibacterial activity. In each
case the results were statistically significant. This agrees
with reports in the literature since inhibition of the growth
of different strains of E. coli has been demonstrated by
coriander [94,95], fennel [94-97], lavender [94,98,99],
lemon balm [98], lemon grass [94,98,100,101], mandarin
[98,102], peppermint [94,96,97,99,103], pine [104], rose-
mary [96,97,105,106], sage [96,106], tea tree [94,107] thyme
[96,107,108], and ylang ylang [94]. Most of these reports
used disc diffusion assays or growth inhibition assays to de-
termine the minimum inhibitory concentration of essential
oils that would inhibit the growth of E. coli. In this present
study, coriander seed, fennel, mandarin, peppermint, sage,
tea tree and thyme essential oils all blocked the growth of
E. coli in a turbidometric assay as well, whereas lavender,
lemon balm, lemon grass, pine and rosemary oils exhibited
strong antibacterial activity in this assay, at least for six
hours, the approximate length of time that would elapse
between doses of a theoretical IBS medicine, which would
be taken before breakfast, lunch, dinner, and possibly bed
time. Any one of these essential oils, or a mixture of them,would be a potential candidate for the reversal of SIBO
and treatment of IBS. The advantages of using a mixture of
essential oils rather than a single oil are that the larger
number of compounds would act on a wider range of bac-
teria, the oils might act synergistically to have a stronger ef-
fect on any given bacterium (as has been documented for
thyme and anise (Pimpinella anisum) oils [109]), and there
would be a reduced chance of producing resistant bacteria.
Coriander seed, lemon balm, peppermint and tea tree
essential oils demonstrated strong antibacterial effects
against E. coli in a zone of clearance assay (and pine had
a more moderate effect), indicating that they are bacteri-
ocidal towards E. coli. Of these, coriander seed, lemon
balm and peppermint essential oils are on the FDA list of
food additives that are generally recognised as safe to
ingest [82]. Indeed peppermint and coriander seed essen-
tial oils displayed higher antibacterial activity in a disc dif-
fusion assay with E. coli DH5α than rifaximin, considered
to be the antibiotic of choice for treating SIBO [34]. Thus
coriander seed, lemon balm and peppermint essential oils
would be very good candidates for the treatment of IBS,
either singly or in combination, since they would be able
to kill bacteria that were already present in the small intes-
tine as SIBO, rather than just inhibiting their growth.
The compounds present in these three essential oils
were identified by thermal desorption gas chromatography
mass spectrometry; many have been reported to have
antibacterial activity. Antibacterial activity against E. coli
has been documented for linalool [98,100,108,110-113],
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which are all present in coriander seed oil; citronellal
[112], geraniol/nerol [98,100,108,111,112,115,116], citro-
nellol [111], and isopulegol [117], which are present in
lemon balm oil; limonene [102,108,110,113,118], which is
present in both coriander seed and lemon balm oil; as well
as caryophyllene [113], which is present in lemon balm
and peppermint oil; and eucalyptol [100,110,111,119],
menthol [100,110] and menthone [100,108,118], which are
all present in peppermint oil. Citral, which is usually re-
ported to be a major constituent of lemon balm oil, but
was present only at a low level in the lemon balm oil that
we used, has also been shown to have antibacterial activity
against E. coli [98,100,108,112,115].
Lemon balm essential oil varies enormously in its
chemical composition. This can be due to the use of dif-
ferent plant lines or cultivars [83-85], variation in plant
growth conditions such as climate/soil [83] or salinity
[86], harvesting at different points in the growing season,
or in different years [84], different harvest cut height
[120], use of either fresh or dried plant material to pro-
duce the essential oil [84] and storage of the essential
oil, since citral levels decrease with storage time [84].
Citral levels have been shown to range between 3.1 +/-
0.35% and 5.4 +/- 0.12%, in essential oils from plants
that were grown in the presence of salt and harvested at
the full bloom stage [86], to between 10.86% and 64.56%
in essential oils from plants that were not flowering [84],
with Cosge et al. [85] reporting intermediate citral levels
between 10.1% and 17.43% and higher citronellal levels
between 36.62% and 43.78%. Patora et al. hypothesised
that citral is converted to citronellal as the plant ages
[84]. This highlights the need to conduct rigorous qual-
ity control analysis, if lemon balm (or any herbal prod-
uct) is to be used medicinally. Further work is ongoing
in our laboratory to investigate the variation in the
chemical composition and antibacterial activity of differ-
ent batches of lemon balm oil (and other essential oils)
obtained from different companies, and to analyse the
antibacterial activity of the individual compounds in the
oils, with the aim of informing eventual quality control
analysis of essential oils for use as medicines. We have
several batches of lemon balm oil from the same com-
pany as the one that we used in this study, with very
similar chemical composition, and several batches from
another company with higher concentrations of citral.
For more in depth evaluation of essential oils, the use of
more appropriate separation technologies such as chiral
columns would aid the identification and separation of the
various isomeric forms common in essential oils. Further-
more, the use of systems such as Kovats retention index
would produce data independent of the chromatographic
setting, which could be readily compared with the litera-
ture and hence aid identification [78].Carmint (a mixture of coriander, lemon balm and
spearmint extracts) has been demonstrated to reduce
IBS symptoms [66]. Our findings with the essential oils
of coriander seed, lemon balm and peppermint sug-
gested that carmint’s efficacy may be due to antibacterial
activity, and the ability to reverse gastrointestinal dysbio-
sis or SIBO. To investigate this further, extracts were
made of coriander, lemon balm and spearmint leaves
using a variety of solvents, and tested for their antibac-
terial activity. In each case, extracts made with ethanol
or methanol displayed the most potent antibacterial ac-
tivity, and since carmint is assumed to contain ethanolic
extracts of the herbs, this suggests that carmint is effect-
ive against IBS because it has antibacterial activity. Other
properties may also contribute to carmint’s mechanism
of action, however, since both peppermint and lemon
balm essential oils and extracts have been shown to have
antispasmodic activity [57,58], peppermint has also been
shown to act on serotonin receptors [121] and lemon
balm reduces stress [122] and could therefore modulate
the gut-brain axis.
Peppermint and lemon balm extracts are also present in
the mixed herbal extract, IberogastW, or STW-5, which has
also been shown to be effective against IBS in a clinical trial
[63]. This suggests that antibacterial activity may also
underlie IberogastW’s mechanism of action, in addition to its
documented antispasmodic, anti-inflammatory, antioxidant
and prosecretory effects [55,62]. This hypothesis is further
strengthened by the fact that IberogastW has been shown in
clinical trials to be effective in treating functional dyspepsia
[64], which has been linked to infection with Helicobacter
pylori and can be treated with antibiotics [123].
There has been one case study that suggested that
enteric-coated peppermint oil tablets could reduce SIBO.
Treatment of a patient with IBS and SIBO with enteric-
coated peppermint oil tablets for 20 days resulted in a
32% reduction in hydrogen and methane excretion at
the 60 minute time-point of a lactulose breath test (six
days after the end of treatment), which correlated with
an improvement in the IBS symptoms of pain, bloating,
eructation and altered bowel habit [124]. The was
ascribed to an antibacterial effect of the peppermint oil
in the capsules reducing bacterial numbers in the small
intestine, although it has been suggested that the treat-
ment may instead have altered gastrointestinal transit
time [125]. It is debatable whether enteric-coated
peppermint oil tablets would be able to reverse SIBO in
all patients, however, because they are designed to
uncoat in the lower intestine in order to exert an anti-
spasmodic effect on the colon, and thus may traverse
much of the small intestine intact. The type of enteric-
coated peppermint oil capsules that were used in the
study was not identified, which is relevant because dif-
ferent types vary in their pharmacokinetics. MintecW
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to peak release of 2.8 h, and display an intense release of
peppermint oil, whereas ColperminW tablets uncoat later
with a lag time of 1.07 h and a time to peak release of
5 h and have a more steady release profile [126,127].
Thus MintecW tablets would be more likely to be able to
address SIBO. It could be argued that peppermint water
[61] would be better still, although it would be import-
ant not to have too high a dose, since it could cause
heartburn due to relaxation of the oesophageal sphincter
[128], and also tachycardia [129]. Whether the patient
whose case study was reported [124], had achlorhydria,
which might have caused the enteric-coated peppermint
oil tablets to uncoat early [130], was not addressed.
Some of the other herbs whose essential oils have been
shown to have antibacterial properties in this current
study are also present in herbal medicines that have
been proposed to be useful for treating IBS, or used to
treat digestive disorders in the past. Mandarin is present
in the Chinese herbal medicine Tong Xie Yao Fang
(TXYF), and a modified version TXYFa, which has been
shown by a systematic review to be potentially effective
in the treatment of IBS, since it reduced abdominal pain,
distension, flatulence and diarrhoea for up to 6 months
after treatment [131]. Absinthe contains fennel (shown
in this study and others to have antibacterial properties)
as well as wormwood (Artemisia absinthium L.), anise
and often lemon balm, Roman wormwood (Artemisia
pontica L.) and hyssop (Hyssopus officinalis L.) [132]. Al-
though absinthe is now thought of as an alcoholic bever-
age, with unhappy connotations due to its ability to
cause absinthism when drunk to excess, it was originally
used in the 1780s to cure colic (aka IBS) and fight
dysentery, which would correlate with its probable anti-
bacterial activity.
Conclusions
New treatments are needed for IBS. Since IBS has been
linked to intestinal dysbiosis or small intestinal bacter-
ial overgrowth, we have investigated the antibacterial
activity of the essential oils of a range of culinary and
medicinal herbs, many of which have traditionally been
used as digestives or are present in herbal medicines
that have been shown to be effective in treating IBS in
clinical trials, in three assays: the disc diffusion assay,
the turbidometric assay and the zone of clearance assay.
Of the essential oils that are on the FDA list of essential
oils that are generally recognised as safe to ingest, cori-
ander seed, lemon balm and peppermint essential oils
exhibited strong antibacterial activity in all three assays,
suggesting that the reason why carmint is effective for
treating IBS is because it has antibacterial activity. The
fact that ethanolic extracts of coriander, lemon balm
and spearmint leaves all exhibited antibacterial activity,provided more evidence to support this hypothesis.
Since other herbal medicines that have been shown/
proposed to be useful in treating IBS and other digest-
ive disorders, contain essential oils or extracts with
antibacterial activity, we hypothesise that antibacterial
properties are an important mechanism of action for
herbal IBS medicines. We consider that essential oils of
coriander seed, lemon balm and peppermint and other
antibacterial essential oils on the FDA GRAS list, as
well as carmint and IberogastW all warrant further
investigation in mechanistic studies and randomised,
double-blind, placebo controlled clinical trials to assess
their ability to act on intestinal dysbiosis or SIBO and
resolve the symptoms of IBS.
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